We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors

- Advanced Solid Tumors
- Recruiting

Study Title: A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors

Teva Identifier: TV56278-ONC-10203

ClinicalTrials.gov Identifier: NCT06480552

Study Status: Recruiting

Trial Condition(s): Advanced Solid Tumors

Interventions: Drug: TEV-56278

Study Description: The primary objectives of this trial are to: -Characterize the safety and tolerability of TEV-56278 -Determine the Recommended Phase 2 Dose (RP2D) -Evaluate antitumor activity of TEV-56278 -Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab -Determine a RP2D of TEV-56278 in combination with pembrolizumab

Click for participation criteria and map of study locations

cancer icon for clinical trials

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years to 64 Years

Trial Duration: July 22, 2024 - February 25, 2031

Phase: Phase 1

Study Type

Interventional